GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Trial details
- Registry ID
- NCT03815825
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ISIS 696844
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)NCT03815825 | IONS | Phase 2 | Completed | 2024-04-18Actual |
| A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyNCT04014335 | IONS | Phase 2 | Completed | 2024-02-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |